EP3583122A4 - Anticorps monoclonaux et cocktails pour le traitement d'infections par le virus ebola - Google Patents
Anticorps monoclonaux et cocktails pour le traitement d'infections par le virus ebola Download PDFInfo
- Publication number
- EP3583122A4 EP3583122A4 EP18754083.6A EP18754083A EP3583122A4 EP 3583122 A4 EP3583122 A4 EP 3583122A4 EP 18754083 A EP18754083 A EP 18754083A EP 3583122 A4 EP3583122 A4 EP 3583122A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cocktails
- treatment
- monoclonal antibodies
- ebola infections
- ebola
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460200P | 2017-02-17 | 2017-02-17 | |
PCT/US2018/018559 WO2018152452A1 (fr) | 2017-02-17 | 2018-02-17 | Anticorps monoclonaux et cocktails pour le traitement d'infections par le virus ebola |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3583122A1 EP3583122A1 (fr) | 2019-12-25 |
EP3583122A4 true EP3583122A4 (fr) | 2020-11-11 |
Family
ID=68578582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18754083.6A Pending EP3583122A4 (fr) | 2017-02-17 | 2018-02-17 | Anticorps monoclonaux et cocktails pour le traitement d'infections par le virus ebola |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP3583122A4 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017156423A2 (fr) * | 2016-03-11 | 2017-09-14 | Integrated Biotherapeutics, Inc. | Cocktails d'anticorps largement protecteurs pour le traitement de la fièvre hémorragique à filovirus |
-
2018
- 2018-02-17 EP EP18754083.6A patent/EP3583122A4/fr active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017156423A2 (fr) * | 2016-03-11 | 2017-09-14 | Integrated Biotherapeutics, Inc. | Cocktails d'anticorps largement protecteurs pour le traitement de la fièvre hémorragique à filovirus |
Non-Patent Citations (5)
Title |
---|
ANNA Z. WEC ET AL: "Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses", CELL, vol. 169, no. 5, 1 May 2017 (2017-05-01), AMSTERDAM, NL, pages 878 - 890.e15, XP055510476, ISSN: 0092-8674, DOI: 10.1016/j.cell.2017.04.037 * |
ANNA Z. WEC ET AL: "Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection", CELL HOST & MICROBE, vol. 25, no. 1, 1 January 2019 (2019-01-01), NL, pages 39 - 48.e5, XP055736663, ISSN: 1931-3128, DOI: 10.1016/j.chom.2018.12.004 * |
See also references of WO2018152452A1 * |
Z. A. BORNHOLDT ET AL: "Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak (Author Manuscript)", SCIENCE, vol. 351, no. 6277, 18 February 2016 (2016-02-18), pages 1078 - 1083, XP055549012, ISSN: 0036-8075, DOI: 10.1126/science.aad5788 * |
Z. A. BORNHOLDT ET AL: "Supplemental material Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak", SCIENCE, 18 February 2016 (2016-02-18), pages 1 - 39, XP055736566, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/suppl/2016/02/17/science.aad5788.DC1/aad5788-Bornholdt-SM.pdf> [retrieved on 20201005], DOI: 10.1126/science.aad5788 * |
Also Published As
Publication number | Publication date |
---|---|
EP3583122A1 (fr) | 2019-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276164A (en) | Antibodies against TMPRSS2 and antigen-binding fragments | |
EP3538152A4 (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
EP3244926B8 (fr) | Traitement du cancer avec des anticorps monoclonaux anti-lap | |
TWI799432B (zh) | 抗ctla-4抗體及其用途 | |
EP3399989A4 (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
EP3426686A4 (fr) | Anticorps anti-pacap humanisés et leurs utilisations | |
EP3414573A4 (fr) | Nouveaux anticorps monoclonaux anti-lam et anti-pim6/lam pour le diagnostic et le traitement d'infections par le bacille de koch | |
EP3797123A4 (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
EP3176182A4 (fr) | Anticorps monoclonal anti-pd-1 et son procédé d'obtention | |
EP3472200A4 (fr) | Anticorps anti-myostatine et leurs procédés d'utilisation | |
EP3307322A4 (fr) | Anticorps humanisés anti-cd40 et leurs utilisations | |
AU2016219350A8 (en) | Humanized anti-MUC1* antibodies | |
EP3280440A4 (fr) | Anticorps anti-c1s humanisés et leurs procédés d'utilisation | |
EP3675906A4 (fr) | Anticorps anti-tm4sf1 et leurs procédés d'utilisation | |
EP3291837A4 (fr) | Cocktails d'anticorps monoclonaux pour le traitement d'infections à ebola | |
EP3846850A4 (fr) | Anticorps humanisés anti-c5 et leurs utilisations | |
EP3733705A4 (fr) | Anticorps monoclonaux et procédés de leur utilisation | |
ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
EP3893931A4 (fr) | Méthodes d'utilisation d'anticorps anti-trem2 | |
EP3183002A4 (fr) | Anticorps monoclonaux pour le traitement d'infections microbiennes | |
EP3529274A4 (fr) | Anticorps monoclonal et procédé d'utilisation pour le traitement du lupus | |
EP3149046A4 (fr) | Anticorps humanisé anti-cd19 et utilisation associée | |
EP3867272A4 (fr) | Utilisation d'anticorps anti-fam19a5 | |
EP4061847A4 (fr) | Anticorps monoclonal anti-b7-h3 et ses procédés d'utilisation | |
EP3404042A4 (fr) | Anticorps monoclonal fnab8 et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190823 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHANDRAN, KARTIK Inventor name: BORNHOLDT, ZACHARY, A. Inventor name: WALKER, LAURA Inventor name: WEC, ANNA Inventor name: ZEITLIN, LARRY |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201014 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/10 20060101AFI20201008BHEP Ipc: A61K 39/395 20060101ALI20201008BHEP Ipc: A61P 31/14 20060101ALI20201008BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MAPP BIOPHARMACEUTICAL, INC. Owner name: ADIMAB, LLC Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE |